Viral Inactivation Market Report 2026

The viral inactivation market size has grown rapidly in recent years. It will grow from $5.47 billion in 2025 to $6.05 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing production of plasma-derived products, expansion of monoclonal antibody manufacturing, rising regulatory emphasis on viral safety, growth of biopharmaceutical manufacturing capacity, wider adoption of solvent detergent methods.

The viral inactivation market size is expected to see rapid growth in the next few years. It will grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to increasing demand for biologics and biosimilars, rising investments in advanced bioprocessing facilities, growing focus on continuous manufacturing, increasing adoption of automated quality control systems, expansion of vaccine production pipelines. Major trends in the forecast period include increasing adoption of automated viral inactivation systems, rising demand for validated virus safety processes, growing use of continuous flow inactivation methods, expansion of single-use bioprocessing solutions, enhanced focus on process reproducibility and compliance.

Growing instances of various infectious diseases are expected to drive the growth of the viral inactivation market in the coming years. Infectious diseases are conditions that can be transmitted from one individual to another through contaminated food and beverages or via pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation plays a key role in human disease-control programs by using physical and chemical disinfectants to neutralize viruses, thereby preventing the spread of contagious viral infections, which contributes to the expansion of the viral inactivation market. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, the number of tuberculosis cases in the United States increased from 8,320 in 2022 to 9,615 in 2023, a rise of 1,295 cases. The incidence rate also rose from 2.5 per 100,000 persons in 2022 to 2.9 per 100,000 in 2023. Therefore, the growing instances of various infectious diseases are driving the viral inactivation market.

Major companies operating in the viral inactivation market are focusing on adopting advanced viral-clearance technologies to enhance biologic safety, regulatory compliance, and process efficiency. These technologies, which inactivate viruses through chemical, physical, or filtration-based methods, enable capabilities such as log-reduction validation, regulatory-compliant viral safety assurance, and faster decision-making in biologics development. For instance, in May 2025, Northway Biotech, a Lithuania-based contract development and manufacturing organization (CDMO), launched Full-Service Viral Clearance Studies (VCS), an advanced viral-clearance solution designed to accelerate safety validation for protein biologics and gene therapies. The service features multiple identical BSL-2 laboratories for high-throughput workflows, BSL-3 testing capabilities, and delivery of fully regulatory-compliant viral clearance results in under 10 weeks, significantly faster than industry norms. This offering enhances development speed, cost control, and regulatory readiness for biopharma clients.

In November 2025, Croda International Plc, a UK-based specialty ingredients company, entered into a strategic partnership with Amino GmbH. Through this collaboration, Croda and Amino aim to expand global access to high-purity amino acids for pharmaceutical formulation and biomanufacturing, enabling faster therapy development, consistent availability of regulatory-grade raw materials, improved sustainability, and enhanced manufacturing efficiency. Amino GmbH, a Germany-based manufacturer of pharmaceutical-grade amino acids, brings advanced precision-manufacturing expertise tailored for pharmaceutical and nutritional applications.

Major companies operating in the viral inactivation market are Merck & Co. Inc., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Pall Corporation And Eurofins Scientific, Cytiva, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG.

North America was the largest region in the viral inactivation market in 2025. Asia-pacific is expected to be the fastest-growing region in the global viral inactivation market during the forecast period. The regions covered in the viral inactivation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral inactivation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the viral inactivation market by increasing costs of imported bioprocessing equipment, filtration systems, reagents, and automation components used in pharmaceutical and biotechnology manufacturing. North America and Europe are most affected due to reliance on specialized imported systems, while Asia-Pacific faces higher costs in scaling viral safety infrastructure. These tariffs are increasing capital expenditure for biomanufacturers and slowing equipment upgrades. However, they are also encouraging domestic production of bioprocessing systems, regional reagent manufacturing, and localized validation services, strengthening long-term supply chain resilience.

The viral inactivation market research report is one of a series of new reports that provides viral inactivation market statistics, including viral inactivation industry global market size, regional shares, competitors with a viral inactivation market share, detailed viral inactivation market segments, market trends and opportunities, and any further data you may need to thrive in the viral inactivation industry. This viral inactivation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral inactivation refers to the process of eliminating viral contamination by exposing bioprocess fluids to conditions that denature viral proteins while preserving the active ingredients of the product. It is most commonly applied in blood plasma processing and monoclonal antibody production.

The main products of viral inactivation include kits and reagents, systems, and services. The solvent detergent method involves damaging the lipid membrane of enveloped viruses, leading to their inactivation. This method is used in plasma to safely neutralize all lipid-enveloped viruses. Viral inactivation methods typically include the solvent detergent method, pH adjustment, pasteurization, and others, and are applied in vaccines and therapeutics, tissues and tissue products, blood and blood products, and other applications. End users include pharmaceutical and biotechnology companies, contract research organizations, blood banks, hospitals, academic research institutes, and other facilities.

The viral inactivation market includes revenues earned by chemical viral inactivation and radiation viral inactivation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.